Assistant Professor Shady Farah from the Technion – Israel Institute of Technology’s Faculty of Chemical Engineering – has led an international research team that pioneered the development of an implantable, self-regulating device that produces insulin for patients with diabetes. The research is considered groundbreaking and could potentially eliminate the need for daily insulin shots.
The multinational study was conducted in cooperation with scientists from leading U.S. institutions, including the Massachusetts Institute of Technology (MIT), Harvard University, Johns Hopkins University and the University of Massachusetts.
The study, published last month in Science Translational Medicine, describes the implant as a self-regulating ‘artificial pancreas’ that monitors blood glucose levels and produces insulin internally, eliminating the need for external insulin shots. The researchers describe the technology as a ‘crystalline shield’ and report that it can operate in the body for years.
Technion researchers developed an implantable artificial pancreas that produces insulin, potentially eliminating daily shots for diabetes patients.







